The clinical pharmacist was involved in the whole process of drug treatment and monitoring of a patient with ulcerative colitis (UC) and facial aseptic abscesses. After admission, clinical pharmacists and physicians jointly formulated an empirical anti-infection plan for meropenem and linezolid glucose injection. After the 5th day of medication, the patient continued to have high fever. After discussion with the physician and clinical pharmacist, it was considered that the patient's facial boil was caused by aseptic abscess syndrome, and UC with extraintestinal manifestations could not be ruled out. Hydrocortisone succinate sodium was added intravenously. After the 9th day of treatment, the patient's facial abscesses improved. Subsequently, the physician followed the clinical pharmacist's advice and used infliximab as the subsequent treatment plan. After the 11th day of treatment, the patient's symptoms improved significantly. During the 2-month follow-up, the facial abscesses completely disappeared, the stool was normal, and there were no special discomforts. The participation of clinical pharmacists in clinical practice improves patients' understanding of the disease and treatment compliance, providing patients with individualized medication support to ensure the safety and effectiveness of medication.

1.中华医学会消化病学分会炎症性肠病学组. 炎症性肠病诊断与治疗的共识意见（2018年·北京）[J]. 中国实用内科杂志, 2018, 38(9): 796-813. [Inflammatory Bowel Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association. Chinese consensus on diagnosis and treatment of inflammatory bowel disease (Beijing, 2018)[J]. Chinese Journal of Practical Internal Medicine, 2018, 38(9): 796-813.] DOI: 10.19538/j.nk2018090106.

2.丁香玉, 李承新. 消化系统疾病的皮肤表现综述[J]. 解放军医学院学报, 2022, 43(1): 106-109. [Ding XY, Li CX. Skin manifestations of digestive diseases: a literature review[J]. Academic Journal of Chinese PLA Medical School, 2022, 43(1): 106-109.] DOI: 10.3969/j.issn.2095-5227.2022.01.020.

3.Lin HS, Lin PT, Tsai YS, et al. Interventions for bacterial folliculitis and boils (furuncles and carbuncles)[J]. Cochrane Database Syst Rev, 2021, 2(2): Cd013099. DOI: 10.1002/14651858.CD013099.pub2.

4.Lally A, Casabonne D, Imko-Walczuk B, et al. Prevalence of benign cutaneous disease among Oxford renal transplant recipients[J]. J Eur Acad Dermatol Venereol, 2011, 25(4): 462-470. DOI: 10.1111/j.1468-3083.2010.03814.x.

5.Rogler G, Singh A, Kavanaugh A, et al. Extraintestinal manifestations of inflammatory bowel disease: Current concepts, treatment, and implications for disease management[J]. Gastroenterol, 2021, 161(4): 1118-1132.DOI: 10.1053/j.gastro. 2021.07.042.

6.李彬彬, 许翠林, 胡乃中, 等. 临床药师参与1例克罗恩病合并多形红斑患者的药物治疗与监护[J] 药物流行病学杂志, 2024, 33(9): 1074-1080. [Li BB, Xu CL, Hu NZ, et al. Clinical pharmacists participated in the drug therapy and pharmaceutical care of a patient with Crohn's disease complicated with erythema multiforme[J] Chinese Journal of Pharmacoepidemiology, 2024, 33(9): 1074-1080.] DOI: 10.12173/j.issn.1005-0698.202407014.

7.Fillman H, Riquelme P, Sullivan PD, et al. Aseptic abscess syndrome[J]. BMJ Case Rep, 2020, 13(10): e236437. DOI: 10.1136/bcr-2020-236437.

8.Gundersen IM, Bruun T, Almeland SK, et al. Necrotising soft tissue infections[J]. Tidsskr Nor Laegeforen, 2024, 144(3). DOI: 10.4045/tidsskr.23.0720.

9.Gros B, Kaplan GG. Ulcerative colitis in adults: A review[J]. JAMA, 2023, 330(10): 951-965. DOI: 10.1001/jama.2023.15389.

10.中华医学会消化病学分会炎症性肠病学组, 中国炎症性肠病诊疗质量控制评估中心. 中国溃疡性结肠炎诊治指南（2023年·西安）[J]. 胃肠病学, 2024, 29(3): 145-173. [Disease Group, Chinese Society of Gastroenterology, Chinese Medical Association; Inflammatory Bowel Disease Quality Control Center of China. Chinese Clinical Practice Guideline on Management of Ulcerative Colitis(2023, Xi'an)[J]. Chinese Journal of Gastroenterology, 2024, 29(3): 145-173.] DOI: 10.3969/j.issn.1008-7125.2024.03.003.

11.冉艳, 邵佳媛, 陈思玮, 等. 《炎症性肠病肠外表现的欧洲循证共识》的解读[J]. 胃肠病学和肝病学杂志, 2020, 29(9): 987-991. [Ran Y, Shao JY, Chen SW, et al. Introduction of the first European evidence-based consensus on extra-intestinal manifestations in inflammatory bowel disease[J]. Chinese Journal of Gastroenterology and Hepatology, 2020, 29(9): 987-991.] DOI: 10.3969/j.issn.1006-5709.2020.09.007.

12.Shahidi N, Bressler B, Panaccione R. The role of vedolizumab in patients with moderate-to-severe Crohn's disease and ulcerative colitis[J]. Therap Adv Gastroenterol, 2016, 9(3): 330-338. DOI: 10.1177/1756283X16635081.

13.Chu X, Biao Y, Liu C, et al. Network Meta-analysis on efficacy and safety of different biologics for ulcerative colitis[J]. BMC Gastroenterol, 2023, 23(1): 346. DOI: 10.1186/s12876-023-02938-6.

14.Peyrin-Biroulet L, Van Assche G, Gómez-Ulloa D, et al. Systematic review of tumor necrosis factor antagonists in extraintestinal manifestations in inflammatory bowel disease[J]. Clin Gastroenterol Hepatol, 2017, 15(1): 25-36. e27. DOI: 10.1016/j.cgh.2016.06.025.

15.Singh S, Murad MH, Fumery M, et al. First-and second-line pharmacotherapies for patients with moderate to severely active ulcerative colitis: An updated network Meta-analysis[J]. Clin Gastroenterol Hepatol, 2020, 18(10): 2179-2191. DOI: 10.1016/j.cgh.2020.01.008.

16.Greuter T, Navarini A, Vavricka SR. Skin manifestations of inflammatory bowel disease[J]. Clin Rev Allergy Immunol, 2017, 53(3): 413-427. DOI: 10.1007/s12016-017-8617-4.